| February 10, 2020 | VIA EDGAR |
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ada D. Sarmento
| RE: | Inovio Pharmaceuticals, Inc. |
Registration Statement on FormS-3
Filed January 31, 2020
File No. 333-236202
Acceleration Request
Requested Date: | February 13, 2020 | |
Requested Time: | 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on FormS-3 (the “Registration Statement”) to become effective on February 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Jeffrey Libson of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703)456-8053.
Very truly yours,
| Inovio Pharmaceuticals, Inc. |
| /s/ Peter Kies |
Peter Kies Chief Financial Officer |
| cc: | Brian Leaf, Cooley LLP |
Jeffrey Libson, Cooley LLP
